Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics License Application resubmissions and approvals.

Despite the reassuring regulatory update and recent earnings and guidance announcements, Alvotech’s share price has been under pressure, with the 30 day share price return down 8.31% and the year to date share price return down 33.80%, while the 1 year total shareholder return has fallen 68.36%. This suggests momentum has been weak even as investors reassess regulatory and earnings risks.

If this kind of regulatory news has you rethinking your sector exposure, it could be a good time to look at other healthcare companies applying AI to drug development and manufacturing via the 32 healthcare AI stocks

With the stock down sharply over the past year and trading at an apparent discount to analyst targets and some valuation metrics, should you view Alvotech as undervalued today, or is the market already pricing in its future growth?

Most Popular Narrative: 76.4% Undervalued

With Alvotech’s fair value in the most followed narrative set at $14.00 against a last close of $3.31, the gap between story and share price is wide.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.

Curious what earnings path, revenue build up and margin shift need to line up for that fair value to make sense? The narrative leans on ambitious growth, richer profitability and a premium future multiple working together. The full breakdown shows exactly how those moving parts are stitched into a single valuation story.

Result: Fair Value of $14.00 (UNDERVALUED)

However, the story only holds if regulatory timelines stay on track and if the heavy reliance on milestone payments does not expose you to sharper than expected earnings swings.

Next Steps

With a mixed setup of risks and potential rewards in play, it makes sense to check the figures directly and form your own view using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that better fit your goals, risk comfort and income needs. Consider widening your view before making your next move.

• Target higher quality value opportunities by scanning 51 high quality undervalued stocks that combine attractive prices with solid fundamentals.
• Strengthen your income focus by reviewing 13 dividend fortresses that aim to deliver robust yields supported by underlying cash flows.
• Dial down portfolio risk by filtering for 65 resilient stocks with low risk scores that score well on balance sheet strength and earnings stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.